with benefit (sometimes limited) reported in some studies 10 -15 but not in others. 16 -18 Most of these studies are small retrospective analyses, lacking sufficient power to identify potentially important benefits. We took advantage of the Mayo Clinic prostatectomy database to examine the role of anaesthetic management in prostate oncological outcomes. Started in 1967, the Mayo Clinic Radical Prostatectomy Registry now includes more than 23 000 patients, which makes it one of the world's largest prostatectomy databases. Furthermore, fewer than 5% of patients have been lost to follow-up. Availability of the prostatectomy registry allowed us to compare oncological outcomes between two specific anaesthetic techniques using large groups that were closely matched on clinically relevant baseline prognostic characteristics and systematically followed for the outcomes of interest. Specifically, we tested the hypotheses that the combination of general and neuraxial anaesthesia reduces cancer recurrence, systemic cancer progression, cancer mortality, and allcause mortality in patients having radical prostatectomy for adenocarcinoma. 10 19 Despite the fact that previous retrospective analyses on this subject are available, our report is unique because it is based on information from the large and well-balanced prostate cancer patient population.
Methods
This study was approved by the Institutional Review Board (IRB) of Mayo Clinic, Rochester, MN, USA. Consistent with Minnesota Statute 144.335 Sub. 3a. (d), we included only patients who have provided authorization for research use of their medical records. We used our institutional prostatectomy registry, anaesthesia database, and electronic medical records to identify patients who had radical prostatectomy for adenocarcinoma from January 1, 1991 , to December 31, 2005 . This period was selected to reduce the potential for including the more advanced prostate cancers that were common before prostate-specific antigen (PSA) was introduced into clinical practice in the late 1980s. The prostatectomy registry uses dedicated abstractors and research nurses who prospectively maintain the registry by contacting patients annually. In addition, reported cancer recurrences are specifically confirmed by directly contacting each patient's primary physician.
The purpose of the present study was to compare oncological outcomes in patients who received general anaesthesia supplemented by neuraxial anaesthesia/analgesia with those who had general anaesthesia only. During the study period, general anaesthesia was usually induced with propofol or sodium thiopental, fentanyl, midazolam, and succinylcholine or vecuronium. Anaesthesia was then maintained with isoflurane, desflurane, or sevoflurane with or without nitrous oxide. When general anaesthesia was supplemented by neuraxial blocks (general/neuraxial), the most typical approach was a single intrathecal spinal injection of 12-15 mg of 0.5% bupivacaine combined with either morphine (0.3-0.6 mg) or hydromorphone (50-60 mg). Less frequently, general anaesthesia was supplemented with epidural analgesia, typically with a loading dose of local anaesthetic (0.5% or 0.75% bupivacaine or 2% lidocaine) and fentanyl (100 mg), followed by an epidural infusion of fentanyl (10 mg ml 21 ) at a rate of 7-12 ml h 21 for two to three postoperative days.
Patients given general/neuraxial anaesthesia were 1:1 matched with those given general anaesthesia only. Patients were matched on age (+5 yr), surgical year (+5 yr), pathological stage (exact) (T2, T3/4, TxN+), pathological Gleason scores (exact) (≤6, 7, ≥8), positive lymph nodes (yes, no, exact), and preoperative PSA (+1.0 ng ml 21 ).
Prostate cancer staging was performed according to the American Joint Committee on Cancer 1997 TNM cancer classification system. 20 Pathology was reviewed by Mayo Clinic staff pathologists and urologists. Adjuvant therapy given in the form of androgen deprivation or radiotherapy was at the discretion of the surgeon and patient, and was defined as any therapy given within 90 days of surgery. Positive surgical margins were noted from pathology reports.
Patients at Mayo Clinic are typically asked to have physical examinations and serum PSA measurement quarterly for the initial 2 postoperative years, 6 monthly for an additional 2 years; and annually thereafter. Our registry collects information regarding biochemical recurrence (defined as postoperative PSA concentrations ≥0.4 ng ml 21 ), 21 local recurrence (reports of clinical examination or prostate bed needle biopsy), and systemic progression defined by the presence of metastatic deposits on imaging (bone scan, computerized tomography, X-ray, or magnetic resonance imaging), or positive biopsies from locations other than the prostatic bed. A small number of patients (,5%) did not follow the recommended follow-up schedule, and presented with local tumour recurrence or even systemic progression without having earlier PSA check-ups; in such cases, elevated PSA levels were detected simultaneously with the diagnosis of a more advanced stage of tumour spread. For that reason, we report an oncological outcome of cancer recurrence, which included patients who had prostate cancer recurrence diagnosed with any of the following: biochemical progression, local recurrence, and/or systemic progression.
Death was presumed to be from prostate cancer when patients died within 30 postoperative days of surgery, or if medical records or death certificate listed prostate cancer as a cause. In general, vital status was determined from death certificates, from yearly correspondence with patients' personal physicians, or both.
Data were abstracted from electronic medical records and entered manually into the web-based Research Electronic Data Capture (REDCap) system (Version 3.6.7, Vanderbilt University, Nashville, TN, USA). 22 We recorded age, body mass index, ASA physical status, preoperative PSA, pathological stage, pathological Gleason score, presence of positive surgical margins, positive lymph node disease, and adjuvant hormonal or radiotherapy. Systemic cancer progression (metastases) and mortality were also recorded. Relevant comorbidities were obtained from medical records, and we ascertained patient comorbidities using previously described definitions, 23 including coronary artery disease, hypertension, current tobacco use, pulmonary disease (obstructive or restrictive chronic lung disease), diabetes mellitus, cerebrovascular disease (stroke, transient ischaemic attacks), peripheral vascular disease, severe kidney disease (associated with kidney replacement therapy), and history of other cancers. In addition, anaesthesia records were reviewed to obtain anaesthetic technique, including neuraxial management. All intraoperative and postoperative i.v. and oral opioids given within the first 48 h were converted to i.v. morphine equivalents. 24 For each patient, opioids administered in the operating theatre, recovery room, and for the first 24 and 48 h after operation were recorded. Neuraxial opioid use was recorded, but not included in our assessment of systemic administration. While systemic morphine has been shown to alter lymphocytic proliferative responses, intrathecal morphine does not affect peripheral lymphocyte function, and therefore does not exert the same immunosuppressive effects induced by systemic administration. 25 
Statistical analysis
Characteristics of patients receiving general anaesthesia only and those receiving both general and neuraxial anaesthesia were summarized using descriptive statistics and compared using two-sample t, rank-sum, or x 2 tests. Prostate cancer recurrence, systemic progression, and mortality were compared using the Kaplan -Meier and log-rank tests. Our primary outcomes were covariate-adjusted: (i) systemic progression; (ii) cancer recurrence; (iii) prostate cancer mortality; and (iv) allcause mortality. Stratified proportional hazards regression, taking into account the matched design, was used to assess differences in outcomes between the general anaesthesia only and general/neuraxial patients. Multivariable analysis was adjusted for baseline PSA, positive surgical margins, adjuvant hormonal or radiotherapy, and comorbidities. But because of the small number of prostate cancer deaths, the multivariable analysis of this outcome was restricted to baseline PSA, positive surgical margins, and adjuvant hormonal or radiotherapy.
Results are presented as point estimates and 95% confidence intervals (CIs). All tests were two-sided, with P≤0.05 considered statistically significant. Statistical analyses were done using SAS statistical software version 9.1.3 (SAS Institute, Inc., Cary, NC, USA).
Results
Between 1991 and 2005, a total of 10 971 patients who had prostatectomy were considered for study inclusion. Among these, 175 were eliminated because they declined authorization to use their medical records for research. A total of 10 796 patients were thus considered. Within this group, we identified 1642 patients who had RRP under general/neuraxial anaesthesia. These patients were 1:1 matched with those who were given general anaesthesia only. Most of the patients (n¼1362, 83%) were given neuraxial analgesia in the form of a spinal block with morphine and, less frequently, hydromorphone. Table 1 shows patient characteristic and clinicopathological characteristics for the two groups. By virtue of exact matching, age, pathological stage, pathological Gleason scores, and number of patients with positive lymph nodes were identical. However, ASA physical status and rates of several comorbid conditions were greater in general anaesthesia-only patients. Also, these patients had a higher rate of positive surgical margins (27% vs 19%, P,0.001), and greater receipt of adjuvant radiation treatment (3% vs 2%, P¼0.002). In contrast, patients given general/neuraxial anaesthesia were more likely to receive adjuvant androgen deprivation therapy (10% vs 4%, P,0.001).
Perioperative opioids used included morphine, fentanyl, hydrocodone, hydromorphone, meperidine, oxycodone, oxymorphone, propoxyphene, and sufentanil. Table 2 is a summary of neuraxial opioids given. Table 3 summarizes the perioperative use of systemic opioids expressed in i.v. morphine equivalents. As expected, systemic opioid use was reduced in patients given general/neuraxial anaesthesia, although not entirely eliminated.
The median (25th, 75th percentiles) follow-up after prostatectomy was 8.6 (6.8, 10.3) yr in general/neuraxial patients and 9.0 (6.4, 11.7) yr in general anaesthesia-only patients. Oncological outcomes and all-cause death in the two groups are shown in Figure 1 and Table 4 . Table 5 shows findings from the stratified proportional hazards regression analyses for our major outcomes. Taking into account the 1:1 matched study design, but not adjusting for additional covariates, general anaesthesia only was associated with increased risk for systemic cancer progression (metastases) [ Relatively few patients died from prostate cancer, which precluded conducting the fully adjusted multivariable model; after adjusting for positive surgical margins and adjuvant therapies, there was some evidence suggesting general anaesthesia only had a higher rate of prostate cancer deaths, although the difference was not statistically significant (adjusted HR¼2.2, 95% CI 0.88-5.60; P¼0.091). Our composite outcome of cancer recurrence (see the Methods section) did not differ significantly on either univariable or multivariable analysis.
Discussion
Our report joins previous studies in examining the role of type of anaesthesia and opioid-sparing effect of neuraxial analgesia on oncological outcomes; some of these studies show benefits 10 -15 and some do not. 16 18 Besides several retrospective studies, there is also one trial in which 446 patients, most of whom had colon resection for cancer, were randomized to general anaesthesia only or general anaesthesia with epidural analgesia. Patients assigned to epidural analgesia had less pain and used less opioid; however, the risk of recurrence was comparable with each anaesthetic approach. 17 It is important, though, to recognize that that particular trial was not primarily designed to examine oncological outcomes, and that cancer recurrence was an unplanned post hoc analysis. 17 Despite the fact that retrospective analyses on the role of regional anaesthesia on cancer outcomes are available, our report is based on the largest and most homogeneous cancer patient population available so far; therefore, it offers a potential for fresh and more accurate insights on this subject. Most previous studies were small, and thus had limited ability to adjust for potential confounding factors, and lacked power to detect potentially clinically important treatment Table 2 Intraoperative neuraxial opioids administered to general/ neuraxial group patients. SD, standard deviation. *Of the 1642 patients who received general anaesthesia/neuraxial block, 1541 had received neuraxial opioids, including 17 patients who received both intrathecal morphine and fentanyl, and two patients who received both intrathecal hydromorphone and fentanyl. Of the 101 patients who did not receive intraoperative neuraxial opioids, 81 had general/epidural (with local anaesthetic only), and 20 received general/spinal anaesthetic (with local anaesthetic only). Of 81 patients with general/epidural, 49 patients received postoperative fentanyl infusion (10 mg ml 21 at rate between 7 and 12 ml h effects. In contrast, our study included 1642 patients in each treatment modality who were matched on key factors potentially associated with oncological outcomes. Our most important finding is that, when neuraxial analgesia was added to general anaesthesia for open retropubic prostatectomy, the rate of systemic tumour progression was significantly reduced and survival improved. However, given our retrospective study design, these findings do not prove causality. To date, three reports examine associations between neuraxial anaesthesia and oncological outcomes after prostatectomy. The first, a retrospective review of 225 patients, reported that regional analgesia reduces biochemical prostate cancer recurrence. 10 The second retrospective study, which included 261 patients, reported a reduced risk for clinical prostate cancer progression, but no significant differences in biochemical recurrence-free, cancer-specific, or overall survival.
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A third, underpowered study examined biochemical recurrence in 99 patients who were included in a previous randomized trial unrelated to oncological outcomes, 26 and reported no significant effect of epidural analgesia on prostate cancer recurrence. 18 In our study, systemic cancer progression and all-cause mortality were significantly reduced by the combination of general and neuraxial anaesthesia. Although not statistically significant on multivariable analysis, prostate cancer death was also reduced. One might expect to find systemic tumour progression to closely correlate with prostate cancer death, because once systemic progression (metastases) is diagnosed, it invariably leads to death. 27 For example, Pound and colleagues 27 showed that in patients with prostate cancer metastases, cancer-specific death equals overall survival rate. The actuarial median time from the development of prostate cancer metastases to cancer-specific death is slightly ,5 yr; however, patients who progressed to systemic disease between 1 and 3 yr after surgery died at a higher rate than those who developed metastases between 4 and 7, or more than 8 yr after surgery. 27 Therefore, it is likely that with longer follow-up, our general anaesthesia group, with a higher rate of systemic progression, would eventually realize a higher rate of prostate cancer deaths. Similarly, one might expect neuraxial anaesthesia to have a greater effect on prostate cancer death than all-cause mortality. But cancer-specific mortality is often underestimated as it may be notoriously difficult to precisely assess. And of course, all-cause mortality is the most reliable outcome, and least susceptible to measurement error.
Tumour recurrence would normally be expected to precede systemic progression; however, the diagnosis of cancer recurrence depends on patient compliance with follow-up. Finally, PSA 21 and digital rectal examinations for local recurrence are less definitive endpoints than radiologically detected and/or biopsy-proven tumour metastasis. For example, biochemical recurrence depends on the accuracy of the PSA assay used (while the majority were performed at Mayo Clinic laboratories, a substantial number of reports were obtained from other labs). 21 We thus believe that using systemic progression, based on imaging or biopsy, is a more reliable outcome than tumour recurrence in our cohort.
Strengths and limitations
Our study differs from previous ones in that it is large enough to use exact matching on the major factors determining progression of prostate cancer, and multivariable modelling for remaining unbalanced factors. Within the limits of retrospective analyses, this approach probably provides the best protection against confounding-although it certainly does not eliminate all sources of error. Any study spanning more than 15 yr, such as ours, is at risk of temporal improvements in surgical and anaesthetic management, especially if the use of the intervention-of-interest varies over time. However, we partially attenuated this concern by matching patients according to the year of surgery (see the Methods section). Although we matched on key clinical and pathological characteristics, a number of comorbidities differed between the two study groups. Perhaps the most important imbalance was a higher rate of positive surgical margins in general anaesthesia-only patients. However, surgical margins are not associated with systemic prostate cancer progression, cancerspecific death, or overall mortality in our patient population. 28 All imbalanced factors were included in multivariable analysis. It nonetheless remains certain that there is a degree of unmeasured confounding factors that we could not include in our statistical adjustment-and it is impossible to determine the extent to which unmeasured factors may have contributed to our conclusions.
We are unable to attribute which component(s) of neuraxial anaesthesia improved oncological outcomes. We hypothesize that a reduction in systemic opioids is an important potential component to improved outcome, but this assumption is speculative and other components may have played a role. For example, some local anaesthetics-notably lidocainehave distinct systemic effects independent from their action on nerve conduction. 29 Another possibility is that patients who received neuraxial anaesthesia would require lower concentration of volatile anaesthetic. Ideally, one might compare general anaesthesia only with neuraxial anaesthesia only. However, neuraxial anaesthesia only is rarely used for major prolonged abdominal surgery. Thus, like several other authors, 10 -15 we evaluated the more common clinical situation in which neuraxial analgesia is combined with general anaesthesia for major surgery. Pain scores were not recorded in most of our patients; analgesic efficacy thus could not be evaluated. However, many previous studies document that epidural blocks provide excellent analgesia, whereas pain is otherwise usually substantial after general anaesthesia only.
All our patients had open surgery, whereas a roboticallyassisted laparoscopic approach is now more common. Because laparoscopic surgery produces less tissue injury, and consequently less surgical stress, the putative benefits of neuraxial analgesia may be diminished in patients having minimally invasive surgery.
Conclusions
Supplementing general anaesthesia with neuraxial analgesia for prostate oncologic surgery was associated with decreased systemic cancer progression and improved overall survival when compared with general anaesthesia only. This finding cannot be used to determine what element of anaesthetic management (e.g. intrathecal opioids, local anaesthetics) or mechanism (reduced stress response, or reduced systemic opioids) may have contributed to the apparent benefit. And, as in any retrospective analysis, unidentified confounding factors may have contributed. Although our results suggest the possibility of the beneficial effects of regional anaesthetic techniques in some oncological outcomes after prostatectomy, we caution that the results from an observational study, such as ours, can only be viewed as hypothesisgenerating and need to be confirmed (or refuted) in future prospective, randomized trials.
